Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes.

Saved in:
Bibliographic Details
Title: Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes.
Authors: Frazer M; QualityMetric, Johnston, RI USA.; Optum, 11000 Optum Circle Eden Prairie, Eden Prairie, MN 55344 USA., Swift C; Novo Nordisk Inc., Plainsboro, NJ USA., Sargent A; Optum, 11000 Optum Circle Eden Prairie, Eden Prairie, MN 55344 USA., Leszko M; Optum, 11000 Optum Circle Eden Prairie, Eden Prairie, MN 55344 USA., Buysman E; Optum, 11000 Optum Circle Eden Prairie, Eden Prairie, MN 55344 USA., Gronroos NN; Optum, 11000 Optum Circle Eden Prairie, Eden Prairie, MN 55344 USA., Alvarez S; Novo Nordisk Inc., Plainsboro, NJ USA., Dunn TJ; Novo Nordisk Inc., Plainsboro, NJ USA., Noone J; Novo Nordisk Inc., Plainsboro, NJ USA., Gamble CL; Novo Nordisk Inc., Plainsboro, NJ USA.
Source: Journal of diabetes and metabolic disorders [J Diabetes Metab Disord] 2023 Nov 27; Vol. 23 (1), pp. 727-737. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101590741 Publication Model: eCollection Cited Medium: Print ISSN: 2251-6581 (Print) Linking ISSN: 22516581 NLM ISO Abbreviation: J Diabetes Metab Disord Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2251-6581
DOI:10.1007/s40200-023-01341-y